Two Sigma Advisers’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-827,500
| Closed | -$1.55M | – | 1528 |
|
|
2025
Q4 | $1.55M | Buy |
+827,500
| New | +$1.59M | ﹤0.01% | 1288 |
|
|
2025
Q3 | – | Sell |
-25,000
| Closed | -$31K | – | 2551 |
|
|
2025
Q2 | $31K | Sell |
25,000
-77,500
| -76% | -$89.5K | ﹤0.01% | 2278 |
|
|
2025
Q1 | $121K | Sell |
102,500
-65,400
| -39% | -$100K | ﹤0.01% | 2218 |
|
|
2024
Q4 | $307K | Buy |
167,900
+27,800
| +20% | +$54.3K | ﹤0.01% | 1969 |
|
|
2024
Q3 | $238K | Buy |
140,100
+17,900
| +15% | +$29.4K | ﹤0.01% | 2004 |
|
|
2024
Q2 | $167K | Sell |
122,200
-22,200
| -15% | -$44.8K | ﹤0.01% | 2249 |
|
|
2024
Q1 | $542K | Sell |
144,400
-7,400
| -5% | -$43.3K | ﹤0.01% | 1838 |
|
|
2023
Q4 | $1.49M | Sell |
151,800
-22,600
| -13% | -$185K | ﹤0.01% | 1441 |
|
|
2023
Q3 | $1.46M | Sell |
174,400
-20,400
| -10% | -$233K | ﹤0.01% | 1361 |
|
|
2023
Q2 | $2.59M | Buy |
194,800
+30,200
| +18% | +$367K | 0.01% | 1056 |
|
|
2023
Q1 | $1.91M | Sell |
164,600
-22,400
| -12% | -$223K | ﹤0.01% | 1296 |
|
|
2022
Q4 | $1.53M | Sell |
187,000
-796,000
| -81% | -$6.86M | ﹤0.01% | 1375 |
|
|
2022
Q3 | $5.71M | Sell |
983,000
-2,597,600
| -73% | -$14.9M | 0.02% | 675 |
|
|
2022
Q2 | $15.8M | Buy |
3,580,600
+2,492,300
| +229% | +$15.1M | 0.04% | 380 |
|
|
2022
Q1 | $9.9M | Buy |
1,088,300
+705,900
| +185% | +$8.13M | 0.03% | 527 |
|
|
2021
Q4 | $7.82M | Sell |
382,400
-178,400
| -32% | -$4.31M | 0.02% | 587 |
|
|
2021
Q3 | $14.3M | Buy |
560,800
+53,500
| +11% | +$1.59M | 0.04% | 409 |
|
|
2021
Q2 | $17.7M | Buy |
507,300
+275,500
| +119% | +$8.01M | 0.05% | 365 |
|
|
2021
Q1 | $7.72M | Buy |
+231,800
| New | +$8.11M | 0.02% | 675 |
|
|
2020
Q1 | – | Sell |
-16,600
| Closed | -$85K | – | 2544 |
|
|
2019
Q4 | $85K | Sell |
16,600
-22,000
| -57% | -$112K | ﹤0.01% | 2263 |
|
|
2019
Q3 | $199K | Sell |
38,600
-187,000
| -83% | -$1.05M | ﹤0.01% | 2044 |
|
|
2019
Q2 | $1.36M | Buy |
+225,600
| New | +$1.58M | ﹤0.01% | 1377 |
|
|
2018
Q1 | – | Sell |
-30,700
| Closed | -$81K | – | 2389 |
|
|
2017
Q4 | $81K | Buy |
30,700
+12,000
| +64% | +$42K | ﹤0.01% | 2168 |
|
|
2017
Q3 | $98K | Buy |
+18,700
| New | +$80.4K | ﹤0.01% | 2118 |
|
|
2015
Q1 | – | Sell |
-72,600
| Closed | -$569K | – | 2264 |
|
|
2014
Q4 | $569K | Buy |
+72,600
| New | +$465K | ﹤0.01% | 1527 |
|
Other funds holding PACB
AIM
VCM
NAMA
Two Sigma Advisers's PACB Position: Q1 2026 in Review
Two Sigma Advisers sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 827,500 shares — an estimated $1.55M sold.
Two Sigma Advisers first reported a position in PACB in Q4 2014 and held it in 25 quarters. The position peaked at $17.7M in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- Two Sigma Advisers reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 827,500 Pacific Biosciences shares in Q1 2026, an estimated $1.55M.
- Two Sigma Advisers first reported a position in Pacific Biosciences in Q4 2014 and held it in 25 quarters.
- Two Sigma Advisers's Pacific Biosciences position peaked at $17.7M in Q2 2021.
- 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.